Recruiting A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies NCT07609862 Conditions Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +32 more Locations Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences — Tianjin, China View Trial Details
Recruiting Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies NCT06980116 Conditions Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more Locations LLC ARENSIA Exploratory Medicine — Tbilisi, Georgia IMSP Institute of Oncology, ARENSIA Exploratory Medicine — Chisinau, Moldova Hospital Beata Maria Ana — Madrid, Spain Hospital Fundación Jiménez Diaz — Madrid, Spain View more locations Show fewer locations Loading locations... View Trial Details
Completed A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies NCT05665530 Conditions Acute Myeloid Leukemia (AML), Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Bone Marrow Diseases, +41 more Locations City of Hope — Duarte, California, United States American Oncology Partners of Maryland, PA — Bethesda, Maryland, United States Dana-Farber Cancer Institute — Boston, Massachusetts, United States Laura and Isaac Perlmutter Cancer Center at NYU Langone Health — New York, United States View all 24 locations View more locations Show fewer locations Loading locations... View Trial Details
